Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Feb 12, 2024
Joe Tucker, CEO of Enveric Biosciences, discusses the use of neuroplastogen therapies for the treatment of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. Enveric has developed the Psybrary, a portfolio of compounds inspired by psilocybin that bind to the serotonin receptor in the brain and induce neuroplasticity without the hallucinations. The lead candidate EB-003 is intended to be administered orally and taken regularly as a maintenance therapy.
Joe explains, "This whole neuroplastogen space was recently discovered, and it was discovered through academic research that we're looking at the effects of these agents we call psychedelics, psilocybin being the active ingredient in magic mushrooms and a very well-known psychedelic agent. It was in looking at psilocybin and other molecules known to be psychedelic agents like ayahuasca and LSD and others that scientists realized that what's going on is you're activating a particular receptor in the brain - something called the serotonin 5-HT2A receptor. So, at Enveric we thought this was a great opportunity because of some of the early work that others had done in using the actual magic mushroom."
"This is a whole new area of research and science. It is not known what shape of a molecule will induce a hallucination versus not inducing hallucination, for example, and what shape will strongly induce the neuroplasticity that we're looking for so that the brain can essentially be repaired versus not induce it. So, we had to develop our own internal artificial intelligence tool that was trained by the other molecules that had been designed previously or were naturally occurring. Then, we continued to train it as we made our thousand molecules and got our AI operating more and more intelligent."
#Enveric #Psilocybin #Hallucinogenic #MentalHealth #NeuroplastogenTherapies #NeuropsychiatricDisorders #PTSD #PostTraumaticStressDisorder
